Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS.
Identifieur interne : 001F58 ( PubMed/Corpus ); précédent : 001F57; suivant : 001F59Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS.
Auteurs : Shao Li ; Ruiqin Wang ; Yulong Zhang ; Xuegong Zhang ; A Joseph Layon ; Yanda Li ; Mingzhe ChenSource :
- The American journal of Chinese medicine [ 0192-415X ] ; 2006.
English descriptors
- KwdEn :
- Adolescent, Adult, Aged, Anti-Bacterial Agents (therapeutic use), Antiviral Agents (therapeutic use), Arthralgia (drug therapy), China, Cohort Studies, Combined Modality Therapy, Drug Therapy, Combination, Female, Glucocorticoids (therapeutic use), Hemofiltration, Houttuynia, Humans, Length of Stay (statistics & numerical data), Male, Medicine, Chinese Traditional, Middle Aged, Oxygen Inhalation Therapy, Oxyhemoglobins (analysis), Phytotherapy, Ribavirin (therapeutic use), SARS Virus, Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (mortality), Thymosin (therapeutic use).
- MESH :
- chemical , analysis : Oxyhemoglobins.
- chemical , therapeutic use : Anti-Bacterial Agents, Antiviral Agents, Glucocorticoids, Ribavirin, Thymosin.
- geographic : China.
- drug therapy : Arthralgia, Severe Acute Respiratory Syndrome.
- mortality : Severe Acute Respiratory Syndrome.
- statistics & numerical data : Length of Stay.
- Adolescent, Adult, Aged, Cohort Studies, Combined Modality Therapy, Drug Therapy, Combination, Female, Hemofiltration, Houttuynia, Humans, Male, Medicine, Chinese Traditional, Middle Aged, Oxygen Inhalation Therapy, Phytotherapy, SARS Virus.
Abstract
Severe acute respiratory syndrome (SARS) is an infectious disease and some of its symptoms were clinically indistinguishable of those from similar diseases. This study aimed to find the symptom combinations associated with adverse outcome and the therapeutic effects in a cohort of patients with probable SARS retrospectively. In 2003, 123 SARS cases in Beijing were subjected to a strictly western medicine (WM) treatment, or a combined treatment (WM plus Herba houttuyniae injection, addition of individualized herbal treatments when necessary), of which 115 were followed till death or discharge; 8 were transferred and lost to follow-up. In both treatment groups, clinical manifestations were evaluated daily; development of signs and symptoms, and their possible relationship with outcome, were assessed. The relationships between these sign/symptom complexes and outcome under two treatment protocols were evaluated and differences were noted. Dynamic symptom combinations, dividing into the early, the medium-term and the durational symptom clusters, were identified as likely being related to the adverse outcomes of SARS (p < 0.05, p < 0.01). Compared with a strictly WM treatment, the combined treatment resulted in a longer hospital stay (p = 0.028), a non-statistically significant mortality rate decrease (combined treatment: 9.6% versus WM: 11.1%), and a significant improvement of arthralgia and myalgia (p < 0.05) in the early symptom cluster. Additionally, the combined protocol improved arterial oxyhemoglobin saturation significantly at day 22 (p < 0.05). In conclusion, the progress and outcome of SARS may be associated with specific temporal patterns of development in combination of several non-specific signs and symptom complexes, which are also helpful for evaluating the therapeutic effects on SARS patients.
DOI: 10.1142/S0192415X06004417
PubMed: 17163583
Links to Exploration step
pubmed:17163583Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS.</title><author><name sortKey="Li, Shao" sort="Li, Shao" uniqKey="Li S" first="Shao" last="Li">Shao Li</name><affiliation><nlm:affiliation>Bioinformatics Division, TNLIST and Department of Automaton, School of Medicine, Tsinghua University, Beijing 100084, China. shaoli@mail.tsinghua.edu.cn</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Ruiqin" sort="Wang, Ruiqin" uniqKey="Wang R" first="Ruiqin" last="Wang">Ruiqin Wang</name></author><author><name sortKey="Zhang, Yulong" sort="Zhang, Yulong" uniqKey="Zhang Y" first="Yulong" last="Zhang">Yulong Zhang</name></author><author><name sortKey="Zhang, Xuegong" sort="Zhang, Xuegong" uniqKey="Zhang X" first="Xuegong" last="Zhang">Xuegong Zhang</name></author><author><name sortKey="Layon, A Joseph" sort="Layon, A Joseph" uniqKey="Layon A" first="A Joseph" last="Layon">A Joseph Layon</name></author><author><name sortKey="Li, Yanda" sort="Li, Yanda" uniqKey="Li Y" first="Yanda" last="Li">Yanda Li</name></author><author><name sortKey="Chen, Mingzhe" sort="Chen, Mingzhe" uniqKey="Chen M" first="Mingzhe" last="Chen">Mingzhe Chen</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17163583</idno><idno type="pmid">17163583</idno><idno type="doi">10.1142/S0192415X06004417</idno><idno type="wicri:Area/PubMed/Corpus">001F58</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F58</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS.</title><author><name sortKey="Li, Shao" sort="Li, Shao" uniqKey="Li S" first="Shao" last="Li">Shao Li</name><affiliation><nlm:affiliation>Bioinformatics Division, TNLIST and Department of Automaton, School of Medicine, Tsinghua University, Beijing 100084, China. shaoli@mail.tsinghua.edu.cn</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Ruiqin" sort="Wang, Ruiqin" uniqKey="Wang R" first="Ruiqin" last="Wang">Ruiqin Wang</name></author><author><name sortKey="Zhang, Yulong" sort="Zhang, Yulong" uniqKey="Zhang Y" first="Yulong" last="Zhang">Yulong Zhang</name></author><author><name sortKey="Zhang, Xuegong" sort="Zhang, Xuegong" uniqKey="Zhang X" first="Xuegong" last="Zhang">Xuegong Zhang</name></author><author><name sortKey="Layon, A Joseph" sort="Layon, A Joseph" uniqKey="Layon A" first="A Joseph" last="Layon">A Joseph Layon</name></author><author><name sortKey="Li, Yanda" sort="Li, Yanda" uniqKey="Li Y" first="Yanda" last="Li">Yanda Li</name></author><author><name sortKey="Chen, Mingzhe" sort="Chen, Mingzhe" uniqKey="Chen M" first="Mingzhe" last="Chen">Mingzhe Chen</name></author></analytic><series><title level="j">The American journal of Chinese medicine</title><idno type="ISSN">0192-415X</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Arthralgia (drug therapy)</term><term>China</term><term>Cohort Studies</term><term>Combined Modality Therapy</term><term>Drug Therapy, Combination</term><term>Female</term><term>Glucocorticoids (therapeutic use)</term><term>Hemofiltration</term><term>Houttuynia</term><term>Humans</term><term>Length of Stay (statistics & numerical data)</term><term>Male</term><term>Medicine, Chinese Traditional</term><term>Middle Aged</term><term>Oxygen Inhalation Therapy</term><term>Oxyhemoglobins (analysis)</term><term>Phytotherapy</term><term>Ribavirin (therapeutic use)</term><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (mortality)</term><term>Thymosin (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Oxyhemoglobins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antiviral Agents</term><term>Glucocorticoids</term><term>Ribavirin</term><term>Thymosin</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>China</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthralgia</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Length of Stay</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Cohort Studies</term><term>Combined Modality Therapy</term><term>Drug Therapy, Combination</term><term>Female</term><term>Hemofiltration</term><term>Houttuynia</term><term>Humans</term><term>Male</term><term>Medicine, Chinese Traditional</term><term>Middle Aged</term><term>Oxygen Inhalation Therapy</term><term>Phytotherapy</term><term>SARS Virus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) is an infectious disease and some of its symptoms were clinically indistinguishable of those from similar diseases. This study aimed to find the symptom combinations associated with adverse outcome and the therapeutic effects in a cohort of patients with probable SARS retrospectively. In 2003, 123 SARS cases in Beijing were subjected to a strictly western medicine (WM) treatment, or a combined treatment (WM plus Herba houttuyniae injection, addition of individualized herbal treatments when necessary), of which 115 were followed till death or discharge; 8 were transferred and lost to follow-up. In both treatment groups, clinical manifestations were evaluated daily; development of signs and symptoms, and their possible relationship with outcome, were assessed. The relationships between these sign/symptom complexes and outcome under two treatment protocols were evaluated and differences were noted. Dynamic symptom combinations, dividing into the early, the medium-term and the durational symptom clusters, were identified as likely being related to the adverse outcomes of SARS (p < 0.05, p < 0.01). Compared with a strictly WM treatment, the combined treatment resulted in a longer hospital stay (p = 0.028), a non-statistically significant mortality rate decrease (combined treatment: 9.6% versus WM: 11.1%), and a significant improvement of arthralgia and myalgia (p < 0.05) in the early symptom cluster. Additionally, the combined protocol improved arterial oxyhemoglobin saturation significantly at day 22 (p < 0.05). In conclusion, the progress and outcome of SARS may be associated with specific temporal patterns of development in combination of several non-specific signs and symptom complexes, which are also helpful for evaluating the therapeutic effects on SARS patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17163583</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0192-415X</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2006</Year></PubDate></JournalIssue><Title>The American journal of Chinese medicine</Title><ISOAbbreviation>Am. J. Chin. Med.</ISOAbbreviation></Journal><ArticleTitle>Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS.</ArticleTitle><Pagination><MedlinePgn>937-47</MedlinePgn></Pagination><Abstract><AbstractText>Severe acute respiratory syndrome (SARS) is an infectious disease and some of its symptoms were clinically indistinguishable of those from similar diseases. This study aimed to find the symptom combinations associated with adverse outcome and the therapeutic effects in a cohort of patients with probable SARS retrospectively. In 2003, 123 SARS cases in Beijing were subjected to a strictly western medicine (WM) treatment, or a combined treatment (WM plus Herba houttuyniae injection, addition of individualized herbal treatments when necessary), of which 115 were followed till death or discharge; 8 were transferred and lost to follow-up. In both treatment groups, clinical manifestations were evaluated daily; development of signs and symptoms, and their possible relationship with outcome, were assessed. The relationships between these sign/symptom complexes and outcome under two treatment protocols were evaluated and differences were noted. Dynamic symptom combinations, dividing into the early, the medium-term and the durational symptom clusters, were identified as likely being related to the adverse outcomes of SARS (p < 0.05, p < 0.01). Compared with a strictly WM treatment, the combined treatment resulted in a longer hospital stay (p = 0.028), a non-statistically significant mortality rate decrease (combined treatment: 9.6% versus WM: 11.1%), and a significant improvement of arthralgia and myalgia (p < 0.05) in the early symptom cluster. Additionally, the combined protocol improved arterial oxyhemoglobin saturation significantly at day 22 (p < 0.05). In conclusion, the progress and outcome of SARS may be associated with specific temporal patterns of development in combination of several non-specific signs and symptom complexes, which are also helpful for evaluating the therapeutic effects on SARS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Shao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bioinformatics Division, TNLIST and Department of Automaton, School of Medicine, Tsinghua University, Beijing 100084, China. shaoli@mail.tsinghua.edu.cn</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ruiqin</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yulong</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xuegong</ForeName><Initials>X</Initials></Author><Author ValidYN="Y"><LastName>Layon</LastName><ForeName>A Joseph</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yanda</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Mingzhe</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Am J Chin Med</MedlineTA><NlmUniqueID>7901431</NlmUniqueID><ISSNLinking>0192-415X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010108">Oxyhemoglobins</NameOfSubstance></Chemical><Chemical><RegistryNumber>49717AWG6K</RegistryNumber><NameOfSubstance UI="D012254">Ribavirin</NameOfSubstance></Chemical><Chemical><RegistryNumber>61512-21-8</RegistryNumber><NameOfSubstance UI="D013947">Thymosin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018771" MajorTopicYN="N">Arthralgia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006440" MajorTopicYN="N">Hemofiltration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052859" MajorTopicYN="N">Houttuynia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010108" MajorTopicYN="N">Oxyhemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008517" MajorTopicYN="N">Phytotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012254" MajorTopicYN="N">Ribavirin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013947" MajorTopicYN="N">Thymosin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17163583</ArticleId><ArticleId IdType="pii">S0192415X06004417</ArticleId><ArticleId IdType="doi">10.1142/S0192415X06004417</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001F58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17163583
|texte= Symptom combinations associated with outcome and therapeutic effects in a cohort of cases with SARS.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17163583" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |